ImmuneRegen BioSciences Appoints Hal Siegel, Ph.D. as Senior Director of Product Development & Regulatory Affairs

SCOTTSDALE, Ariz., Jan. 3  /PRNewswire-FirstCall/ -- Research and development biotechnology company ImmuneRegen BioSciences, Inc. a wholly owned subsidiary of IR BioSciences Holdings, Inc. (OTC:IRBO) (BULLETIN BOARD: IRBO) , today announced the appointment of Hal Siegel, Ph.D. as Senior Director of Product Development & Regulatory Affairs.  This formal relationship between Dr. Siegel and ImmuneRegen began October 23, 2006.  In this position, Siegel will help direct the development of ImmuneRegen's proprietary compound, Homspera(TM).

"Dr. Siegel's expertise in FDA protocol and procedure will be invaluable as we gear up for pre-clinical studies on the potential healing effects of Homspera," said Michael K. Wilhelm, ImmuneRegen's CEO.  "He has over a decade of experience delivering scientific, clinical and regulatory compliance assistance as well as in submission preparation and management.  It is that experience that will greatly benefit our strategic plan to make Homspera a staple in all national emergency preparedness stockpiles."

Siegel comes to ImmuneRegen from Zila Inc., where he was VP of Regulatory & Scientific Affairs within Zila's Biotechnology Division.  For over 5 years Dr. Siegel has operated Siegel Consultancy, LLC which provided strategic and tactical expertise to life science companies, enabling them to better meet FDA requirements in pre-clinical studies, the regulatory submission process and the post-approval marketplace.

Previously, as a scientific and regulatory expert for life science activities at Sun Microsystems and BioQ, Inc., as well as at the contract research organizations Advanced Bioresearch Associates and Paragon Biomedical, and companies such as Hybritech, Inc. (an Eli Lilly company), Dr. Siegel provided independent scientific and regulatory consulting advice, and submission writing and management services, as well as represented client interests at FDA meetings and in litigation defense.

Originally trained as a scientific researcher, Dr. Siegel's laboratory experience at the Los Alamos National Laboratory and the Barrow Neurological Institute built on his earlier studies in neurotransmitter receptor-ligand interactions and second messenger signaling.  His degrees are from Rensselaer Polytechnic Institute and SUNY Buffalo (Ph.D., Biochemical Pharmacology).

About ImmuneRegen BioSciences, Inc.

IR BioSciences Holdings Inc., through its wholly owned subsidiary ImmuneRegen BioSciences, Inc., is a development stage biotechnology company focused on the research and development of Homspera(TM) and its derivatives Radilex(TM) and Viprovex(TM).  Homspera is derived from modified Substance P, a naturally occurring peptide immunomodulator. Radilex(TM) is the trade name used in referring to formulations of Homspera for potential indications for the possible treatment of the effects of exposure to ionizing radiation. Viprovex(TM) is the trade name used in referring to formulations of Homspera for potential indications for the possible treatment of the effects of viral and bacterial infections.  Homspera is a generic name used by the Company to describe the synthetic peptide Sar9, Met (O2)11-Substance P. Sar9, Met (O2)11- Substance P is an analog of the naturally occurring human neuropeptide Substance P, which can be found throughout the body, including in the airways of humans and many other species.  All of the Company's research and development efforts are early, pre-clinical stage and Homspera, as Viprovex(TM) and Radilex(TM), has only undergone exploratory studies to evaluate its biological activity in small animals.  For more information, please visit the company's website at http://www.immuneregen.com/.

Statements about the Company's future expectations, including statements about the potential for the Company's drug candidates, science and technology, and all other statements in this press release other than historical facts, are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as that term is defined in the Private Securities Litigation Reform Act of 1995.  The Company intends that such forward-looking statements be subject to the safe harbors created thereby.  These future events may not occur as and when expected, if at all, and, together with the Company's business, are subject to various risks and uncertainties.  The Company's actual results could differ materially from expected results as a result of a number of factors, including the fact that preliminary results involved only a small number of test mice, the subsequent investigations were limited in scope, the uncertainties inherent in research and development collaborations, pre-clinical and clinical trials and product development programs, (including, but not limited to the fact that future results or research and development efforts may prove less encouraging than current results or cause side effects not observed in current pre-clinical trials) the evaluation of potential opportunities, the level of corporate expenditures and monies available for further studies, capital market conditions, and others set forth in the Company's periodic report on Form 10-QSB for the three months ended September 30, 2006 and on Form 10-KSB for the twelve months ended December 31, 2005 as filed with the Securities and Exchange Commission.  There are no guarantees that any of the Company's proposed products will prove to be commercially successful.  The Company undertakes no duty to update forward-looking statements.

  Contact:

           MEDIA CONTACT: W. Jason Grimley
           Spelling Communications
           310-477-9500
           

DATASOURCE: ImmuneRegen BioSciences, Inc.



CONTACT:  W. Jason Grimley of Spelling Communications, [phone],

, for ImmuneRegen BioSciences, Inc.



Web site:  http://www.immuneregen.com/ 

Copyright